The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

被引:85
作者
Donia, Marco [1 ,2 ]
Kimper-Karl, Marie Louise [3 ]
Hoyer, Katrine Lundby [4 ]
Bastholt, Lars [3 ]
Schmidt, Henrik [4 ]
Svane, Inge Marie [1 ,2 ]
机构
[1] Ctr Canc Immune Therapy, Dept Hematol, Herlev, Denmark
[2] Copenhagen Univ Hosp, Dept Oncol, Herlev, Denmark
[3] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[4] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
关键词
Metastatic melanoma; Immunotherapy; Phase III trials; Patient selection; Real-world patients; BRAIN METASTASES; OPEN-LABEL; UNTREATED MELANOMA; IPILIMUMAB; PEMBROLIZUMAB; DABRAFENIB; NIVOLUMAB; RESPONSES; SURVIVAL; BLOCKADE;
D O I
10.1016/j.ejca.2016.12.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent randomised phase III trials have led to the approval of several immune checkpoint inhibitors for unresectable or metastatic melanoma (MM). These trials all employed strict patient selection criteria, and it is currently unknown how large proportion of 'real-world' patients diagnosed with MM is not represented in these trials. Patients and methods: The Danish MM Database contains data on the entire, unselected population of MM within a nationwide geographical area. A total of 276 unselected cases of MM (ocular melanoma excluded), referred for first oncological evaluation in 2014, were included in the analysis. Seven pre-defined eligibility criteria, all used to select patients for enrolment in five recent randomised phase III immunotherapy trials; were analysed. Results: Fifty-five percent of the total population with MM did not meet one or more eligibility criteria ('not eligible' group) at first evaluation. PS >= 2 or active/untreated known brain metastases accounted alone for 74% of non-eligibility cases. Median overall survival in the 'not eligible' group was 5.43 months versus 18.3 months for the eligible (p < 0.0001, hazard ratio (HR) 2.44), reflected by significantly worse baseline prognostic features. However, patients treated with immunotherapy had similar survival outcomes regardless of eligibility. Conclusion: Over half of the patients evaluated for systemic treatment of MM are not represented in phase III registration immunotherapy trials. The data reveal a huge knowledge gap regarding the usefulness of new immunotherapies in the 'real-world' patient population, and urge additional testing of known regimens in selected poor prognosis cohorts. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:89 / 95
页数:7
相关论文
共 22 条
[1]   Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab [J].
Bjoern, Jon ;
Iversen, Trine Zeeberg ;
Nitschke, Nikolaj Juul ;
Andersen, Mads Hald ;
Svane, Inge Marie .
CYTOTHERAPY, 2016, 18 (08) :1043-1055
[2]  
Callahan MK, 2016, CANCER TREAT RES, V167, P231, DOI 10.1007/978-3-319-22539-5_9
[3]   Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival [J].
Delyon, J. ;
Mateus, C. ;
Lefeuvre, D. ;
Lanoy, E. ;
Zitvogel, L. ;
Chaput, N. ;
Roy, S. ;
Eggermont, A. M. M. ;
Routier, E. ;
Robert, C. .
ANNALS OF ONCOLOGY, 2013, 24 (06) :1697-1703
[4]  
Ferlay J, IARC CANCERBASE
[5]   Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].
Goldberg, Sarah B. ;
Gettinger, Scott N. ;
Mahajan, Amit ;
Chiang, Anne C. ;
Herbst, Roy S. ;
Sznol, Mario ;
Tsiouris, Apostolos John ;
Cohen, Justine ;
Vortmeyer, Alexander ;
Jilaveanu, Lucia ;
Yu, James ;
Hegde, Upendra ;
Speaker, Stephanie ;
Madura, Matthew ;
Ralabate, Amanda ;
Rivera, Angel ;
Rowen, Elin ;
Gerrish, Heather ;
Yao, Xiaopan ;
Chiang, Veronica ;
Kluger, Harriet M. .
LANCET ONCOLOGY, 2016, 17 (07) :976-983
[6]   Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial [J].
Hauschild, Axel ;
Grob, Jean-Jacques ;
Demidov, Lev V. ;
Jouary, Thomas ;
Gutzmer, Ralf ;
Millward, Michael ;
Rutkowski, Piotr ;
Blank, Christian U. ;
Miller, Wilson H., Jr. ;
Kaempgen, Eckhart ;
Martin-Algarra, Salvador ;
Karaszewska, Boguslawa ;
Mauch, Cornelia ;
Chiarion-Sileni, Vanna ;
Martin, Anne-Marie ;
Swann, Suzanne ;
Haney, Patricia ;
Mirakhur, Beloo ;
Guckert, Mary E. ;
Goodman, Vicki ;
Chapman, Paul B. .
LANCET, 2012, 380 (9839) :358-365
[7]   Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials [J].
Heng, D. Y. C. ;
Choueiri, T. K. ;
Rini, B. I. ;
Lee, J. ;
Yuasa, T. ;
Pal, S. K. ;
Srinivas, S. ;
Bjarnason, G. A. ;
Knox, J. J. ;
MacKenzie, M. ;
Vaishampayan, U. N. ;
Tan, M. H. ;
Rha, S. Y. ;
Donskov, F. ;
Agarwal, N. ;
Kollmannsberger, C. ;
North, S. ;
Wood, L. A. .
ANNALS OF ONCOLOGY, 2014, 25 (01) :149-154
[8]   Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].
Hodi, F. Stephen ;
O'Day, Steven J. ;
McDermott, David F. ;
Weber, Robert W. ;
Sosman, Jeffrey A. ;
Haanen, John B. ;
Gonzalez, Rene ;
Robert, Caroline ;
Schadendorf, Dirk ;
Hassel, Jessica C. ;
Akerley, Wallace ;
van den Eertwegh, Alfons J. M. ;
Lutzky, Jose ;
Lorigan, Paul ;
Vaubel, Julia M. ;
Linette, Gerald P. ;
Hogg, David ;
Ottensmeier, Christian H. ;
Lebbe, Celeste ;
Peschel, Christian ;
Quirt, Ian ;
Clark, Joseph I. ;
Wolchok, Jedd D. ;
Weber, Jeffrey S. ;
Tian, Jason ;
Yellin, Michael J. ;
Nichol, Geoffrey M. ;
Hoos, Axel ;
Urba, Walter J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723
[9]   Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma [J].
Hugo, Willy ;
Zaretsky, Jesse M. ;
Sun, Lu ;
Song, Chunying ;
Moreno, Blanca Homet ;
Hu-Lieskovan, Siwen ;
Berent-Maoz, Beata ;
Pang, Jia ;
Chmielowski, Bartosz ;
Cherry, Grace ;
Seja, Elizabeth ;
Lomeli, Shirley ;
Kong, Xiangju ;
Kelley, Mark C. ;
Sosman, Jeffrey A. ;
Johnson, Douglas B. ;
Ribas, Antoni ;
Lo, Roger S. .
CELL, 2016, 165 (01) :35-44
[10]   Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders [J].
Johnson, Douglas B. ;
Sullivan, Ryan J. ;
Ott, Patrick A. ;
Carlino, Matteo S. ;
Khushalani, Nikhil I. ;
Ye, Fei ;
Guminski, Alexander ;
Puzanov, Igor ;
Lawrence, Donald P. ;
Buchbinder, Elizabeth I. ;
Mudigonda, Tejaswi ;
Spencer, Kristen ;
Bender, Carolin ;
Lee, Jenny ;
Kaufman, Howard L. ;
Menzies, Alexander M. ;
Hassel, Jessica C. ;
Mehnert, Janice M. ;
Sosman, Jeffrey A. ;
Long, Georgina V. ;
Clark, Joseph I. .
JAMA ONCOLOGY, 2016, 2 (02) :234-240